
Novo Nordisk A/S: stock overview
Price
$40.70
November 17, 2026Market cap $181B
What Ploutos Investor adds for Novo Nordisk A/S
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Novo Nordisk A/S had revenue of $48.6B in the fiscal year to December 31, 2025 and net income of $16.1B, a net margin of 33.1%. Revenue grew by 19.5% a year on average over the last 5 years. At $40.70 the shares trade at a P/E of 11.2, against a median of 35.5 over the last 5 fiscal years. It has net debt of $17.8B. It pays a dividend yielding 4.52%.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 17, 2026.
Its SEC filings- Market cap
- $181B
- 4.44B shares
- P/E
- 11.2
- Today11.2Median35.5
- Revenue, fiscal year
- $48.6B
- +19.5% a year over 5 years
- Net margin
- 33.1%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+15.4% a year over 2 years
Fiscal years in figures
NVO's revenue, profit, cash flow and dividend with each year-end price, from 2019 to 2022, 4 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $382B
- $181B
- Enterprise value
- $199B
- P/E 3-year median: 27.4
- 11.2
- EV / EBIT
- 9.9
- EV / Revenue
- 4.1
- P/B 3-year median: 19.2
- 5.9
- FCF yield 3-year median: 2.7%
- 5.1%
- Earnings yield 3-year median: 3.7%
- 8.9%
Profitability
- Gross margin
- 81.0%
- Operating margin
- 41.3%
- Net margin 3-year median: 34.8%
- 33.1%
- ROIC
- 31.0%
- ROIC, 5-year average
- 46.9%
- ROE, fiscal year
- 52.8%
Growth
- Revenue, yearly change
- +6.4%
- EPS, yearly change
- +1.8%
- FCF, yearly change
- -20.1%
- Revenue, average a year
- +19.5%
- EPS, average a year
- +20.7%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $4.2B
- Total debt
- $21.9B
- Net debt
- $17.8B
- Net debt / EBITDA
- 0.8x
- Interest cover
- –
- Current ratio
- –
Balance sheet of December 31, 2025.
Returns to shareholders
- Dividend yield 3-year median: 1.8%
- 4.52%
- Buybacks
- 0.12%
- Total returned
- 4.64%
- Shares, yearly change
- +0.1%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- NOVO NORDISK A S
- CIK
- 353278
- Exchange
- NYSE
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- DKK
- Shares
- 4.44B
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with NVO
- JNJJohnson & Johnson+0,00%Compare with NVO
- ABBVAbbVie+0,00%Compare with NVO
- UNHUnitedHealth+0,00%Compare with NVO
- MRKMerck & Company+0,00%Compare with NVO
- AMGNAmgen+0,00%Compare with NVO
- TMOThermo Fisher Scientific+0,00%Compare with NVO
- ABTAbbott Laboratories+0,00%Compare with NVO
The full analysis
What do Novo Nordisk A/S's filings show?
These are Novo Nordisk A/S's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is NVO's market cap?
Novo Nordisk A/S's market cap is $181B, at a price of $40.70 on November 17, 2026 and 4.44B shares.
What is NVO's P/E?
NVO's P/E is 11.2, on earnings per share of $3.62 in the fiscal year to December 31, 2025. The median over the last 5 fiscal years was 35.5.
How much revenue does NVO have?
Novo Nordisk A/S had revenue of $48.6B in the fiscal year to December 31, 2025. Over the last 5 years it changed by +19.5% a year on average.
Does NVO pay a dividend?
Yes. Novo Nordisk A/S paid $1.84 per share over the last 12 months, a yield of 4.52% at today's price. All the figures are in the Dividend section.
Where do the figures come from?
From Novo Nordisk A/S's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.